IS7421A - Frásogshvati - Google Patents

Frásogshvati

Info

Publication number
IS7421A
IS7421A IS7421A IS7421A IS7421A IS 7421 A IS7421 A IS 7421A IS 7421 A IS7421 A IS 7421A IS 7421 A IS7421 A IS 7421A IS 7421 A IS7421 A IS 7421A
Authority
IS
Iceland
Prior art keywords
absorption enhancer
enhancer
absorption
Prior art date
Application number
IS7421A
Other languages
English (en)
Inventor
Gizurarson Sveinbjörn
olafsdottir Sigríthur
Líndal Kristinsson Jakob
Hrafnkelsdottir Kolbrun
Rurik olafsson Davíth
Ingolfsson Oddur
Rut Ingimundardottir Ellen
Original Assignee
Lyfjathroun Hf.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lyfjathroun Hf. filed Critical Lyfjathroun Hf.
Publication of IS7421A publication Critical patent/IS7421A/is

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Otolaryngology (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
IS7421A 2002-02-25 2004-08-24 Frásogshvati IS7421A (is)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IS6283 2002-02-25
IS6453 2002-07-03
PCT/IS2003/000010 WO2003070280A2 (en) 2002-02-25 2003-02-24 Absorption enhancing agent

Publications (1)

Publication Number Publication Date
IS7421A true IS7421A (is) 2004-08-24

Family

ID=36763295

Family Applications (2)

Application Number Title Priority Date Filing Date
IS7422A IS7422A (is) 2002-02-25 2004-08-24 Efni með viðloðunareiginleika
IS7421A IS7421A (is) 2002-02-25 2004-08-24 Frásogshvati

Family Applications Before (1)

Application Number Title Priority Date Filing Date
IS7422A IS7422A (is) 2002-02-25 2004-08-24 Efni með viðloðunareiginleika

Country Status (11)

Country Link
US (2) US20050063940A1 (is)
EP (2) EP1480673A1 (is)
JP (1) JP2005519075A (is)
KR (1) KR20040095232A (is)
CN (1) CN1642576A (is)
AU (2) AU2003215884A1 (is)
BR (1) BR0307913A (is)
CA (1) CA2477321A1 (is)
IS (2) IS7422A (is)
NZ (1) NZ534738A (is)
WO (2) WO2003070273A1 (is)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2477321A1 (en) * 2002-02-25 2003-08-28 Lyfjathroun Hf Absorption enhancing agent
WO2005123043A2 (en) * 2004-06-10 2005-12-29 Duramed Pharmaceuticals, Inc. Formulations of sumatriptan for absorption across biological membranes, and methods of making and using the same
TW200824693A (en) 2006-08-28 2008-06-16 Jazz Pharmaceuticals Inc Pharmaceutical compositions of clonazepam and methods of use thereof
WO2008049454A1 (en) * 2006-10-23 2008-05-02 Ecolab Inc. Virucidal composition
WO2009147684A2 (en) * 2008-06-06 2009-12-10 Quark Pharmaceuticals, Inc. Compositions and methods for treatment of ear disorders
RU2519193C2 (ru) 2008-09-12 2014-06-10 Критикал Фармасьютикалс Лимитед Усовершенствование всасывания терапевтических средств через слизистые оболочки или кожу
EP2512231B1 (en) 2009-12-16 2016-12-07 Ecolab Inc. Composition in form of a gel for the virucidal disinfection of mammalian skin
ES2907867T3 (es) 2016-06-20 2022-04-26 Capretto Ehf Formulación estable de lípidos antimicrobianos
WO2020247127A1 (en) * 2019-06-07 2020-12-10 Paxmedica, Inc. Compositions and methods for treating central nervous system disorders
WO2023183557A1 (en) * 2022-03-25 2023-09-28 Neurelis, Inc. Intranasal olanzapine formulations and methods of their use

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3225706C2 (de) * 1982-07-09 1984-04-26 A. Nattermann & Cie GmbH, 5000 Köln Flüssige Wirkstofformulierungen in Form von Konzentraten für Mikroemulsionen
US5019395A (en) * 1988-03-08 1991-05-28 Warner-Lambert Company Compositions with enhanced penetration
DE68909135T2 (de) * 1988-07-21 1994-04-07 Hoffmann La Roche Insulinzubereitung.
US5190748A (en) * 1988-11-22 1993-03-02 Hoffmann-La Roche Inc. Absorption enhancement of antibiotics
ATE183099T1 (de) * 1991-04-19 1999-08-15 Lds Technologies Inc Konvertierbare mikroemulsionsverbindungen
CA2083553A1 (en) * 1991-11-25 1993-05-26 Kuniharu Seki Immunogen composition
US5314685A (en) * 1992-05-11 1994-05-24 Agouron Pharmaceuticals, Inc. Anhydrous formulations for administering lipophilic agents
IT1255895B (it) * 1992-10-20 1995-11-17 Laura Chiodini Composizioni farmaceutiche contenenti una calcitonina
DK17093D0 (da) * 1993-02-15 1993-02-15 Lyfjathroun H F Farmaceutisk praeparat til topisk administrering af antigener og/eller vacciner til pattedyr via slimhinder
GB9320597D0 (en) * 1993-10-06 1993-11-24 Proteus Molecular Design Improvements in and realting to vaccines
US6008228A (en) * 1995-06-06 1999-12-28 Hoffman-La Roche Inc. Pharmaceutical compositions containing proteinase inhibitors
SE9602280D0 (sv) * 1996-06-10 1996-06-10 Pharmatrix Ab Immunstimulerande lipidformulering
IS4516A (is) * 1997-07-01 1999-01-02 Gizurarson Sveinbjörn Nýtt lyfjaform
IS4518A (is) * 1997-07-09 1999-01-10 Lyfjathroun Hf, The Icelandic Bio Pharmaceutical Group Nýtt lyfjaform fyrir bóluefni
DE19756164A1 (de) * 1997-12-17 1999-06-24 Km Europa Metal Ag Verfahren zur Herstellung eines Kokillenkörpers und Kokillenkörper
FR2773489B1 (fr) * 1998-01-15 2001-03-23 Immunotech Sa Nouvelle composition destinee a la voie oromuqueuse notamment pernasale
ES2234324T3 (es) * 1998-11-02 2005-06-16 MERCK & CO., INC. Combinaciones de un agonista 5ht1b/1d y un inhibidor selectivo de cox-2 para el tratamiento de la migraña.
US6267985B1 (en) * 1999-06-30 2001-07-31 Lipocine Inc. Clear oil-containing pharmaceutical compositions
US20030104048A1 (en) * 1999-02-26 2003-06-05 Lipocine, Inc. Pharmaceutical dosage forms for highly hydrophilic materials
US6294192B1 (en) * 1999-02-26 2001-09-25 Lipocine, Inc. Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents
US7374779B2 (en) * 1999-02-26 2008-05-20 Lipocine, Inc. Pharmaceutical formulations and systems for improved absorption and multistage release of active agents
US6761903B2 (en) * 1999-06-30 2004-07-13 Lipocine, Inc. Clear oil-containing pharmaceutical compositions containing a therapeutic agent
EP1034792A1 (en) * 1999-03-11 2000-09-13 Pasteur Merieux Serums Et Vaccins Intranasal delivery of pneumococcal polysaccharide vaccines
US6383471B1 (en) * 1999-04-06 2002-05-07 Lipocine, Inc. Compositions and methods for improved delivery of ionizable hydrophobic therapeutic agents
US6309663B1 (en) * 1999-08-17 2001-10-30 Lipocine Inc. Triglyceride-free compositions and methods for enhanced absorption of hydrophilic therapeutic agents
US6458383B2 (en) * 1999-08-17 2002-10-01 Lipocine, Inc. Pharmaceutical dosage form for oral administration of hydrophilic drugs, particularly low molecular weight heparin
US20030236236A1 (en) * 1999-06-30 2003-12-25 Feng-Jing Chen Pharmaceutical compositions and dosage forms for administration of hydrophobic drugs
US20030235595A1 (en) * 1999-06-30 2003-12-25 Feng-Jing Chen Oil-containing, orally administrable pharmaceutical composition for improved delivery of a therapeutic agent
US6468559B1 (en) * 2000-04-28 2002-10-22 Lipocine, Inc. Enteric coated formulation of bishosphonic acid compounds and associated therapeutic methods
US6495596B1 (en) * 2001-03-23 2002-12-17 Biozibe Laboratories, Inc. Compounds and methods for inhibition of phospholipase A2 and cyclooxygenase-2
CA2457595A1 (en) * 2001-08-16 2003-02-27 Lyfjathroun H.F., Biopharmaceuticals A method of producing antibodies ex-vivo
AU2002357930B2 (en) * 2001-12-19 2007-06-28 Alza Corporation Formulation & dosage form for the controlled delivery of therapeutic agents
CN1273130C (zh) * 2001-12-20 2006-09-06 布里斯托尔-迈尔斯斯奎布公司 具有增大的生物利用率的口服活性紫杉烷衍生物的药物组合物
CA2477321A1 (en) * 2002-02-25 2003-08-28 Lyfjathroun Hf Absorption enhancing agent
US20050163787A1 (en) * 2002-02-25 2005-07-28 Lyfjathroun Hf, Biopharmaceutical Immunological adjuvant
EP1509209A1 (en) * 2002-05-23 2005-03-02 UMD, Inc. Compositions and method for transmucosal drug delivery and cryoprotection
US6855332B2 (en) * 2002-07-03 2005-02-15 Lyfjathroun Hf. Absorption promoting agent

Also Published As

Publication number Publication date
US20050106122A1 (en) 2005-05-19
BR0307913A (pt) 2005-01-11
EP1480673A1 (en) 2004-12-01
WO2003070280A2 (en) 2003-08-28
AU2003215884A1 (en) 2003-09-09
IS7422A (is) 2004-08-24
CA2477321A1 (en) 2003-08-28
WO2003070280A3 (en) 2004-05-13
US20050063940A1 (en) 2005-03-24
WO2003070273A1 (en) 2003-08-28
KR20040095232A (ko) 2004-11-12
AU2003215885A1 (en) 2003-09-09
JP2005519075A (ja) 2005-06-30
EP1521599A2 (en) 2005-04-13
AU2003215885B2 (en) 2008-07-03
NZ534738A (en) 2007-01-26
CN1642576A (zh) 2005-07-20

Similar Documents

Publication Publication Date Title
IS7872A (is) Pýrrólópýrimidín afleiður
DK3473251T3 (da) Nikotin-cellulose-kombination
ATE457980T1 (de) Aryloxime
ATE534648T1 (de) C-6-modifizierte indazolylpyrrolotriazine
ATE368042T1 (de) Cephemverbindungen
ATE427876T1 (de) Luftkissenboot
ATE318817T1 (de) Aza-arylpiperazine
NO20044046L (no) Substituerte hydroksyetylaminer
IS7381A (is) Efnasambönd
IS7414A (is) Oxó-azabísýklísk efnasambönd
ATE349458T1 (de) Etonogestrelester
ATE446020T1 (de) Calcium-aufnahme verstärker
NO20045659L (no) Forbindelser
ATE496887T1 (de) Substituierte 5-aminomethyl-1h-pyrrol-2-carbons ureamide
ATA1572002A (de) Managementspleisskassette
IS7421A (is) Frásogshvati
ATA4142004A (de) Trägerverbau
ATE469773T1 (de) Zugöse
ATA19152002A (de) Hubkupplung
ATE396192T1 (de) N-sulfonylaminothiazole
ATE350379T1 (de) Substituierte benzdioxepine
DE10244834B8 (de) Suszeptometer
DE10211707A8 (de) Segmentstatormaschine
AT5889U3 (de) Brennholzspleisser
ATA16872002A (de) Zwischenstück